Dr. Clay Siegall is the co-founder of Seattle Genetics, a biotech company that focuses on developing and commercializing targeted therapy cancer drugs for cancers with high mortality rates. Siegall has served as the biotech company’s President and Chief Executive Officer since it was established in 1998. It has come a long way from its humble beginnings as a tiny startup with a small but dedicated team of researchers. Under the leadership of Siegall the company has become a leading innovator in the targeted therapy industry. It is responsible for developing the first FDA-approved antibody drug conjugate.
The founding of Seattle Genetics was both business and personal for Clay Siegall. The idea for the biotech company came from Siegall watching his father’s own cancer steadily progress over five years until his death. after watching his father die the limitations of oncologists at the time became blindingly apparent and since he always had an interest in medicine he decided to help improve the tools available to oncologists. He believed there had to be a better way.
He went on to attend George Washington University and earn his doctorate in genetics. He landed in Seattle after taking a job at Bristol-Myers Squibb, a New York based pharmaceutical company.
Siegall wants Seattle Genetics’ reputation to be a company that improved the quality of life of those suffering from cancer. To him there is no better reward than knowing you’ve changed someone’s life for the better.
Clay Siegall currently serves on the Boards of Directors of three separate companies. Over the years he has received a variety of awards. Two of the biggest accolades he’s ever received came in back to back years and includes Young Entrepreneur of the Year followed by Alumnus of the Year. Siegall is an author as well with 70 published works.